Physician profile
Mark Chang
NPI 1356564934
$4,344.48
in general payments reported to CMS, 2019-2025
34 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $145 · 2021: $273 · 2022: $580 · 2023: $762 · 2024: $769 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.82 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $746.55 | 2019-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $533.51 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $462.09 | 2019-2025 | Erleada |
| Boston Scientific Corporation | $303.92 | 2019-2023 | Ams 700 |
| Bayer Healthcare Pharmaceuticals INC. | $288.50 | 2019-2025 | |
| Pfizer INC. | $202.98 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $185.87 | 2022-2025 | Lynparza, Keytruda, Welireg |
| Coloplast Corp | $185.43 | 2019-2025 | Speedicath |
| Ferring Pharmaceuticals INC. | $144.54 | 2019-2024 | Adstiladrin |
| Urogen Pharma, INC. | $134.79 | 2023-2025 | Jelmyto |
| Urovant Sciences INC | $127.84 | 2022 | |
| Progenics Pharmaceuticals, INC. | $103.04 | 2023-2025 | Pylarify |
| Novartis Pharmaceuticals Corporation | $102.26 | 2025 | |
| Abbvie INC. | $91.94 | 2019-2022 | |
| Myovant Sciences INC. | $82.75 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74.38 | 2019 | |
| Tolmar, INC. | $61.06 | 2024-2025 | Eligard, Jatenzo |
| 180 Medical, INC. | $55.83 | 2022-2023 | Gentlecath |
| Blue Earth Diagnostics | $52.83 | 2021-2024 | |
| Dendreon Pharmaceuticals LLC | $49.98 | 2019-2023 | Provenge |
| Myriad Genetic Laboratories, INC. | $37.50 | 2024 | Prolaris |
| Hollister Incorporated | $36.16 | 2023-2024 | Vapro Pocket |
| Accord Healthcare, INC. | $35.01 | 2024-2025 | |
| Tolmar Pharmaceuticals, INC. | $33.51 | 2022 | |
| Dentsply Ih Ab | $31.82 | 2024 | Lofric |
| Astrazeneca Pharmaceuticals Lp | $29.12 | 2025 | Lynparza |
| Teleflex LLC | $26.91 | 2025 | Barrigel |
| Sun Pharmaceutical Industries INC. | $21.59 | 2025 | |
| Telix Pharmaceuticals | $18.30 | 2025 | Illuccix |
| Medtronic USA, INC. | $18.19 | 2020 | |
| Calyxo, INC. | $17.89 | 2025 | Cvac Aspiration System |
| Endo USA, INC. | $16.99 | 2025 | Xiaflex |
| Abc Home Medical Supply, INC. | $15.84 | 2024 | |
| Therapeuticsmd, INC. | $15.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.